A study published early online in JAMA to coincide with its presentation at the American College of Cardiology's annual scientific sessions, reveals that patients with chest pain who received an intravenous solution of glucose-insulin-potassium (GIK) had no reduced risk of progressing to a heart attack and no improved 30-day survival regardless of GIK's association with lower rates of cardiac arrests or in-hospital deaths...
More...
More...